Answers are grounded in this paper and cite their sources.
Observational analysis highlights metformin's impact on aging and type 2 diabetes, suggesting future therapeutic potential.
The most often given oral hypoglycaemic drug for type 2 diabetes globally is metformin, a biguanide anti-diabetic drug that has been around for more than 30 years. Its mode of action wasn't understood till a few years ago. However, it was recently found that through an increased tissue glucose uptake by a transporter-linked system, is now connected to better peripheral sensitivity to insulin. Although it is clear that not all possible effects of metformin use have been identified yet, it is feasible that metformin will become a cornerstone treatment for illnesses associated with ageing and other related conditions such as cancer and neurological diseases in humans. Despite the fact that not everyone using metformin experiences the same advantages, some people do have negative effects. Therefore, it is essential to fully comprehend the mechanism and all potential side effects of this medication. Therefore, this study offers a summary of current advances in metformin's impact on ageing and illnesses linked to it.
No takes yet. Share an insight, caveat, or question.
Kavinraja. et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: